Jefferies lowers Valneva stock price target to $14 on FDA suspension

Valneva SE shares dropped 21% after the FDA suspended the Biologics License Application for its chikungunya vaccine, IXCHIQ, citing serious adverse events including one death and multiple hospitalizations. This setback led Jefferies to reduce its price target to $14 while maintaining a Buy rating, though H.C. Wainwright initiated coverage with an $18 price target and Buy rating. Investor attention now shifts to the pivotal Phase III data for Valneva's Lyme disease vaccine candidate (VLA15), co-developed with Pfizer, expected by year-end 2025, which analysts identify as the primary future catalyst.

Analysis

Valneva SE faces a significant regulatory setback following the FDA's suspension of its chikungunya vaccine, IXCHIQ, due to serious adverse events, including one death and over 20 hospitalizations. This action triggered a 21% decline in VALN shares, erasing a portion of a recent 51% gain, although the stock remains up 166% year-to-date. Analyst sentiment, while cautious, leans positive on the long-term outlook; Jefferies maintained a Buy rating despite cutting its price target to $14 from $18, while H.C. Wainwright initiated coverage with a Buy rating and an $18 price target. The investment thesis has now pivoted almost entirely to Valneva's pipeline, specifically the VLA15 Lyme disease vaccine being co-developed with Pfizer. The Phase III data for VLA15, expected by year-end 2025, is now the primary catalyst, with Jefferies assigning a 75% probability of success and modeling a potential 50% upside or 25% downside for the stock based on the outcome. The company's financial position is characterized by strong liquidity but current unprofitability, underscoring its high dependency on a successful clinical trial outcome.

Key Decisions for Investors

• Investors should re-evaluate their position in Valneva, as the investment case now hinges on a high-risk, binary outcome from the VLA15 Lyme disease vaccine trial expected by year-end 2025.
• Monitor any further communications from the FDA regarding the IXCHIQ suspension, as a resolution could impact near-term sentiment and cash flow, but the primary valuation driver remains the Lyme vaccine.
• Given the stock's significant year-to-date gains and the 'overbought' signal, consider taking partial profits to de-risk exposure ahead of the long-duration wait for the pivotal VLA15 data readout.